46 results on '"Wenxin keli"'
Search Results
2. Identification of linoleic acid as an antithrombotic component of Wenxin Keli via selective inhibition of p-selectin-mediated platelet activation
- Author
-
Qianqian Tao, Guangxu Xiao, Taiyi Wang, Lei Zhang, Mingxing Yu, Li Peng, Linhong Han, Xiaoli Du, Wenrun Han, Shuang He, Ming Lyu, and Yan Zhu
- Subjects
Wenxin Keli ,Systems pharmacology ,Linoleic acid ,Platelet activation ,Thrombosis ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Atrial fibrillation significantly increases the risk of thromboembolism and stroke. Wenxin Keli (WXKL) is a widely used Chinese patent medicine against arrhythmia but if it has antithrombotic activity is unknown. Since platelet activation is a critical factor in thrombosis and the key target for many antithrombotic drugs, this study aims to demonstrate the antithrombotic efficacy of WXKL. In vitro platelet activation experiments showed that WXKL significantly inhibited platelet adhesion and aggregation. The potential active monomers in WXKL were screened by in silico prediction and in vitro platelet aggregation/adhesion assays. From WXKL chemical fractions and more than 40 monomers, linoleic acid (LA) was identified as the strongest antiplatelet compound. Oral administration of WXKL (1.2 g/kg/day) and LA (50 mg/kg/day) for 7 days significantly improved FeCl3-induced carotid thrombus formation in ICR mice without prolonging bleeding time. Flow cytometry showed that both WXKL and LA inhibited the release of p-selectin after platelet activation. ELISA showed that WXKL and LA also inhibited the expression of 6-Keto-PGF1α in plasma of mice with thrombus, but had no obvious effect on the expression of TXB2. WXKL inhibited platelet activation by broadly inhibiting the phosphorylation of protein kinase B (Akt), mitogen-activated protein kinases (MAPKs) and phospholipase C (PLC) β3. In contrast, LA only inhibited the phosphorylation of PLCβ3. In conclusion, WXKL and its active component LA showed good antiplatelet and antithrombotic efficacy in vivo and in vitro. Mechanistically, the multicomponent Chinese medicine WXKL acts on multiple targets in the platelet activation pathway whereas its active monomer linoleic acid acts specifically on phospholipase C β3.
- Published
- 2022
- Full Text
- View/download PDF
3. Efficacy and safety of Wenxin Keli combined with metoprolol tartrate in the treatment of premature ventricular contractions: A systematic review and meta-analysis
- Author
-
Ping Huang, Yining Luo, Jiaxue Chen, Jingke Xu, Yuanshu Shi, Guoren Chen, and Ping Ma
- Subjects
Wenxin Keli ,metoprolol tartrate ,Ventricular Premature Complexes ,meta-analysis ,safety ,efficacy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
BackgroundWenxin Keli (WXKL) has good clinical value in the treatment of premature ventricular contractions, but there is insufficient evidence to support it. This study evaluates the efficacy and safety of WXKL combined with metoprolol tartrate in the treatment of ventricular premature beats (VPCs).MethodsWe searched seven databases to identify randomized controlled trials (RCTs) for this study. Two reviewers independently screened and extracted the data. The Cochrane Manual criteria were used for methodological quality assessment. Meta-analyses were performed using Review Manager 5.4.1 software. Risk ratios (RR) were used for effect sizes for dichotomous data, demonstrated in effect sizes and 95% confidence intervals (CIs).ResultsA total of 11 RCTs of WXKL combined with metoprolol tartrate in the treatment of premature ventricular contractions were included in this study. Meta-analysis showed that WXKL combined with metoprolol tartrate (treatment group) was more effective than metoprolol tartrate (control group) in improving premature ventricular contractions (RR = 1.32, 95% CI: [1.24, 1.40], P < 0.00001); significantly improved the rate of premature ventricular contractions (RR = 1.32, 95% CI: [1.23, 1.41], P < 0.00001); there was no difference in adverse drug reactions compared with the control group (RR = 0.61, 95% CI: [0.35, 0.1.05], P = 0.08), but the number of adverse reactions (n = 18) was less than that of the control group (n = 32), and the severity was lower than that of the control group. The included studies only mentioned randomization and did not describe the generation of random sequences in detail.ConclusionThis study found that Wenxin Keli combined with metoprolol tartrate in the treatment of premature ventricular contractions increased the efficacy of the drug, reduced the occurrence of adverse reactions, and reduced the severity of adverse reactions. Due to the quality limitations of the included studies, more high-quality RCTs are needed in the future to provide more evidence for longer-term analyses.
- Published
- 2022
- Full Text
- View/download PDF
4. Wenxin Keli for the Treatment of Arrhythmia—Systems Pharmacology and In Vivo Pharmacological Assessment.
- Author
-
Li, Xiaofeng, Tian, Gang, Xu, Liang, Sun, Lili, Tao, Rui, Zhang, Shaoqiang, Cong, Zidong, Deng, Fangjun, Chen, Jinhong, Yu, Yang, Du, Wuxun, and Zhao, Hucheng
- Subjects
ARRHYTHMIA ,PHARMACOLOGY ,INTRACELLULAR calcium - Abstract
This study employed a systems pharmacology approach to identify the active compounds and action mechanisms of Wenxin Keli for arrhythmia treatment. Sixty-eight components identified in vivo and in vitro by UPLC/Q-TOF-MS were considered the potential active components of Wenxin Keli. Network pharmacology further revealed 33 key targets and 75 KEGG pathways as possible pathways and targets involved in WK-mediated treatment, with the CaMKII/CNCA1C/Ca
2+ pathway being the most significantly affected. This finding was validated using an AC-induced rat arrhythmias model. Pretreatment with Wenxin Keli reduced the malignant arrhythmias and shortened RR, PR, and the QT interval. Wenxin Keli exerted some antiarrhythmic effects by inhibiting p-CaMKII and intracellular Ca2+ transients and overexpressing CNCA1C. Thus, suppressing SR Ca2+ release and maintaining intracellular Ca2+ balance may be the primary mechanism of Wenxin Keli against arrhythmia. In view of the significance of CaMKII and NCX identified in this experiment, we suggest that CaMKII and NCX are essential targets for treating arrhythmias. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Wenxin Keli for the Treatment of Arrhythmia—Systems Pharmacology and In Vivo Pharmacological Assessment
- Author
-
Xiaofeng Li, Gang Tian, Liang Xu, Lili Sun, Rui Tao, Shaoqiang Zhang, Zidong Cong, Fangjun Deng, Jinhong Chen, Yang Yu, Wuxun Du, and Hucheng Zhao
- Subjects
Wenxin Keli ,arrhythmia ,active compounds ,action mechanisms ,systems phar macology ,Ca2+ balance ,Therapeutics. Pharmacology ,RM1-950 - Abstract
This study employed a systems pharmacology approach to identify the active compounds and action mechanisms of Wenxin Keli for arrhythmia treatment. Sixty-eight components identified in vivo and in vitro by UPLC/Q-TOF-MS were considered the potential active components of Wenxin Keli. Network pharmacology further revealed 33 key targets and 75 KEGG pathways as possible pathways and targets involved in WK-mediated treatment, with the CaMKII/CNCA1C/Ca2+ pathway being the most significantly affected. This finding was validated using an AC-induced rat arrhythmias model. Pretreatment with Wenxin Keli reduced the malignant arrhythmias and shortened RR, PR, and the QT interval. Wenxin Keli exerted some antiarrhythmic effects by inhibiting p-CaMKII and intracellular Ca2+ transients and overexpressing CNCA1C. Thus, suppressing SR Ca2+ release and maintaining intracellular Ca2+ balance may be the primary mechanism of Wenxin Keli against arrhythmia. In view of the significance of CaMKII and NCX identified in this experiment, we suggest that CaMKII and NCX are essential targets for treating arrhythmias.
- Published
- 2021
- Full Text
- View/download PDF
6. Systemic evaluation and Meta-analysis of Wenxin Keli in treatment of idiopathic premature beats in randomized controlled trails.
- Author
-
Ying Hu, Ling Feng, Ping Li, Ting-Ting Wang, Xing-Juan Chen, and Wei-Na Li
- Subjects
META-analysis ,RANDOMIZED controlled trials ,BISOPROLOL ,ARRHYTHMIA ,METOPROLOL - Abstract
Objective: To evaluate the efficacy and safety of Wenxin Keli for premature beats in structurally normal heart systematically. Methods: Eight databases at home and abroad were searched to collect randomized controlled trials of Wenxin Keli for premature beats without cardiac diseases. The included literatures were systematically evaluated with Cochrane Handbook 5.1 evaluation criteria and tools, and Meta analysis was performed with software RevMan5.3. Results: A total of 13 randomized controlled trials with 1278 subjects were included. The exprimental group used Wenxin Keli alone while the control group used antiarrhythmic medicine. The Meta analysis results showed that the total effective rate(RR=1.06,95%CI [0.97,1.16],P=0.23) and clinical symptom effective rate (RR=1.16,95%CI[0.94, 1.44],P=0.18)of Wenxin Keli on idiopathic premature beats was not significantly different from western medicine group. The subgroup analysis of total effective rate showed that Wenxin Keli had no significant difference with metoprolol (RR=1.04,95%CI[ 0.95,1.15],P=0.41), bisoprolol (RR=1.32,95%CI[0.85,2.05],P=0.22) and propanone(RR=1.07, 95%CI[0.90,1.26],P= 0.44). ECG changes showed that the PR intervals (MD=-12.57,95%CI[-16.15, -8.99],P<0.00001) and QTc intervals (MD=-8.09,95%CI[-15.52, -0.65],P=0.03) in the western medicine group were prolonged significantly more than those of Wenxin Keli. In terms of safety, the incidence of adverse reactions of Wenxin Keli was significantly less than that of western medicine group (RR=0.32,95%CI[0.19, 0.54],P< 0.0001). Conclusion: The efficacy of Wenxin Keli in the treatment of premature beats with structurally normal heart is accurate, and there are no serious adverse reactions. However, because of the low quality of the included papers, which affected the reliability of the conclusions, high-quality clinical research is needed to further demonstrate. [ABSTRACT FROM AUTHOR]
- Published
- 2021
7. Screening and Identification of Cardioprotective Compounds From Wenxin Keli by Activity Index Approach and in vivo Zebrafish Model
- Author
-
Hao Liu, Xuechun Chen, Xiaoping Zhao, Buchang Zhao, Ke Qian, Yang Shi, Mirko Baruscotti, and Yi Wang
- Subjects
Wenxin Keli ,arrhythmia ,zebrafish ,cardioprotection ,drug screen ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Wenxin Keli (WXKL) is a widely used Chinese botanical drug for the treatment of arrhythmia, which is consisted of four herbs and amber. In the present study, we analyzed the chemical composition of WXKL using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) to tentatively identify 71 compounds. Through typical separate procession, the total extract of WXKL was divided into fractions for further bioassays. Cardiomyocytes and zebrafish larvae were applied for assessment. In vivo arrhythmia model in Cmlc2-GFP transgenic zebrafish was induced by terfenadine, which exhibited obvious reduction of heart rate and occurrence of atrioventricular block. Dynamic beating of heart was recorded by fluorescent microscope and sensitive camera to automatically recognize the rhythm of heartbeat in zebrafish larvae. By integrating the chemical information of WXKL and corresponding bioactivities of these fractions, activity index (AI) of each identified compound was calculated to screen potential active compounds. The results showed that dozens of compounds including ginsenoside Rg1, ginsenoside Re, notoginsenoside R1, lobetyolin, and lobetyolinin were contributed to cardioprotective effects of WXKL. The anti-arrhythmic activities of five compounds were further validated in larvae model and mature zebrafish by measuring electrocardiogram (ECG). Our findings provide a successful example for rapid discovery of bioactive compounds from traditional Chinese medicine (TCM) by activity index based approach coupled with in vivo zebrafish model.
- Published
- 2018
- Full Text
- View/download PDF
8. Screening and Identification of Cardioprotective Compounds From Wenxin Keli by Activity Index Approach and in vivo Zebrafish Model.
- Author
-
Liu, Hao, Chen, Xuechun, Zhao, Xiaoping, Zhao, Buchang, Qian, Ke, Shi, Yang, Baruscotti, Mirko, and Wang, Yi
- Abstract
Wenxin Keli (WXKL) is a widely used Chinese botanical drug for the treatment of arrhythmia, which is consisted of four herbs and amber. In the present study, we analyzed the chemical composition of WXKL using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) to tentatively identify 71 compounds. Through typical separate procession, the total extract of WXKL was divided into fractions for further bioassays. Cardiomyocytes and zebrafish larvae were applied for assessment. In vivo arrhythmia model in Cmlc2-GFP transgenic zebrafish was induced by terfenadine, which exhibited obvious reduction of heart rate and occurrence of atrioventricular block. Dynamic beating of heart was recorded by fluorescent microscope and sensitive camera to automatically recognize the rhythm of heartbeat in zebrafish larvae. By integrating the chemical information of WXKL and corresponding bioactivities of these fractions, activity index (AI) of each identified compound was calculated to screen potential active compounds. The results showed that dozens of compounds including ginsenoside Rg
1 , ginsenoside Re, notoginsenoside R1 , lobetyolin, and lobetyolinin were contributed to cardioprotective effects of WXKL. The anti-arrhythmic activities of five compounds were further validated in larvae model and mature zebrafish by measuring electrocardiogram (ECG). Our findings provide a successful example for rapid discovery of bioactive compounds from traditional Chinese medicine (TCM) by activity index based approach coupled with in vivo zebrafish model. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Therapeutic Effects of Wenxin Keli in Cardiovascular Diseases: An Experimental and Mechanism Overview
- Author
-
Guihua Tian, Yang Sun, Shuo Liu, Chengyu Li, Shiqi Chen, Ruijin Qiu, Xiaoyu Zhang, Youping Li, Min Li, and Hongcai Shang
- Subjects
Wenxin Keli ,WXKL ,cardioprotective effects ,antiarrhythmic effects ,mechanism ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Cardiovascular diseases (CVDs) are the major public health problem and a leading cause of morbidity and mortality on a global basis. Wenxin Keli (WXKL), a formally classical Chinese patent medicine with obvious efficacy and favorable safety, plays a great role in the management of patients with CVDs. Accumulating evidence from various animal and cell studies has showed that WXKL could protect myocardium and anti-arrhythmia against CVDs. WXKL exhibited its cardioprotective roles by inhibiting inflammatory reaction, decreasing oxidative stress, regulating vasomotor disorders, lowering cell apoptosis, and protection against endothelial injure, myocardial ischemia, cardiac fibrosis, and cardiac hypertrophy. Besides, WXKL could effectively shorten the QRS and Q-T intervals, decrease the incidence of atrial/ventricular fibrillation and the number of ventricular tachycardia episodes, improve the severity of arrhythmias by regulating various ion channels with different potencies, mainly comprising peak sodium current (INa), late sodium current (INaL), transient outward potassium current (Ito), L-type calcium current (ICaL), and pacemaker current (If).
- Published
- 2018
- Full Text
- View/download PDF
10. Clinical Safety and Efficacy of Wenxin Keli-Amiodarone Combination on Heart Failure Complicated by Ventricular Arrhythmia: A Systematic Review and Meta-analysis
- Author
-
Rui Zheng, Guihua Tian, Qin Zhang, Lin Wu, Yanwei Xing, and Hongcai Shang
- Subjects
Wenxin Keli ,amiodarone ,heart failure complicated with ventricular arrhythmia ,adverse reaction ,systematic review ,meta-analysis ,Physiology ,QP1-981 - Abstract
Objectives: To evaluate possible adverse effects and efficacy of Wenxin keli (WXKL)-amiodarone combination on heart failure complicated by ventricular arrhythmia.Methods: Nine electronic literature databases (the Cochrane Library, PubMed, EMBASE, IPA, AMED, CBM, CNKI, VIP, and WanFang) were searched up to February 2018. Two authors extracted data and assessed risk of bias of the included studies independently. Randomized controlled trials (RCTs) and quasi-RCTs about WXKL-amiodarone combination and amiodarone alone were eligible for comparison.Results: Thirteen trials involving 1,126 patients were included. Risk of bias was assessed as high in three studies and unclear in the remaining 10 studies. Six trials reported adverse events (AE). There was no obvious difference between WXKL-amiodarone combination group and amiodarone group in reported AEs (OR 0.64; 95%CI 0.39–1.07). The total effective rate of WXKL-amiodarone combination group was greater than that of amiodarone group (RR 1.22; 95%CI 1.16–1.29). The pooled results showed that the combination group was more effective in reducing heart rate (MD −2.25; 95%CI −2.61 to −1.88, P = 0.46, I2 = 0%), the frequency of ventricular premature complexes (MD −2.03; 95%CI −2.41 to −1.65) and QT dispersion (MD 5.59; 95%CI 3.60–7.58).Conclusion: The WXKL-amiodarone combination is safe and shows more protective effects on heart failure combined with ventricular arrhythmia compared with amiodarone alone. Further research is warranted, ideally involving large, prospective, rigorous trials, in order to confirm these findings.
- Published
- 2018
- Full Text
- View/download PDF
11. The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial
- Author
-
Wei Hua, Run-Lin Gao, Bu-Chang Zhao, Jing Wang, Xu-Hua Chen, Chi Cai, and Shu Zhang
- Subjects
Wenxin Keli ,Premature Ventricular Contractions ,Efficacy ,Safety ,Clinical Trial ,Medicine - Abstract
Background: Premature ventricular contractions (PVCs) are common in the general population, and frequent PVCs may result in the poor quality of life or even the damage of cardiac function. We examined the efficacy and safety of a traditional Chinese medicine Wenxin Keli for the treatment of frequent PVCs among a relatively large Chinese cohort. Methods: We performed a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. A total of 1200 eligible participants were randomly assigned in a ratio of 1:1 to receive Wenxin Keli or the placebo for 4 weeks. The primary and secondary endpoint was the change of PVC numbers and PVC-related symptoms after a 4-week treatment compared with baseline, respectively. In addition, vital signs, laboratory values, and electrocardiographic parameters were assessed in a safety analysis. Results: At the initial evaluation, no significant differences in the baseline characteristics were observed between the Wenxin Keli group and the placebo group. A smaller number of PVCs was observed after the 4-week treatment than at baseline, in both the Wenxin Keli group (5686 ± 5940 vs. 15,138 ± 7597 beats/d, P < 0.001) and the placebo group (10,592 ± 8009 vs. 14,529 ± 5929 beats/d, P < 0.001); moreover, the Wenxin Keli group demonstrated a significantli greater reduction in the frequency of PVCs than the placebo group (P < 0.001). In a full analysis set, patients in the Wenxin Keli group exhibited significantly higher total effective responses in the reduction of PVCs compared to those in the placebo group (83.8% vs. 43.5%,P < 0.001). The per-protocol analysis yielded similar results (83.0% vs. 39.3%,P < 0.001). Treatment with Wenxin Keli also demonstrated superior performance compared to the placebo with respect to PVC-related symptoms. No severe adverse effects attributable to Wenxin Keli were reported. Conclusions: Wenxin Keli treatment effectively reduced the overall number of PVCs and alleviated PVC-related symptoms in patients without structural heart diseases and had no severe side effects.
- Published
- 2015
- Full Text
- View/download PDF
12. Wenxin Keli diminishes Ca2+ overload induced by hypoxia/reoxygenation in cardiomyocytes through inhibiting INaL and ICaL.
- Author
-
Luo, Antao, Liu, Zhipei, Cao, Zhenzhen, Hao, Jie, Wu, Lin, Fu, Chen, Zeng, Mengliu, Jiang, Wanzhen, Zhang, Peihua, Zhao, Buchang, Zhao, Tao, Zhao, Jing, and Ma, Jihua
- Subjects
- *
ARRHYTHMIA prevention , *HYPOXEMIA , *CALCIUM , *ELECTROCARDIOGRAPHY , *FLUOROSCOPY , *HEART cells , *HERBAL medicine , *CHINESE medicine , *METABOLIC disorders , *MYOCARDIUM , *SODIUM - Abstract
Background An increase in the late sodium current (INaL) causes intracellular Na+ overload and subsequently intracellular Ca2+ ([Ca2+]i) overload via the stimulated reverse Na+-Ca2+ exchange (NCX). Wenxin Keli (WXKL) is an effective antiarrhythmic Chinese herb extract, but the underlying mechanisms are unclear. Methods and results The INaL, NCX current (INCX), L-type Ca2+ current (ICaL), and action potentials were recorded using the whole-cell patch-clamp technique in rabbit ventricular myocytes. Myocyte [Ca2+]i transients were measured using a dual excitation fluorescence photomultiplier system. WXKL decreased the enhanced INaL, reverse INCX, diastolic [Ca2+]i, and the amplitude of Ca2+ transients induced by sea anemone toxin II (ATX II, a specific INaL channel opener) in a concentration-dependent manner. Hypoxia increased INaL, INCX, and diastolic [Ca2+]i, and decreased amplitude of [Ca2+]i transients. Hypoxia-reoxygenation aggravated these changes and induced spontaneous [Ca2+]i transients and hypercontraction in 86% cells (6/7). The application of WXKL during hypoxia or reoxygenation periods decreased the increased INaL, INCX, and diastolic [Ca2+]i, and prevented those events in 82% cells (9/11) under hypoxia-reoxygenation conditions. WXKL also inhibited the ICaL in a dose-dependent manner. Furthermore, WXKL shortened the action potential duration and completely abolished ATX II-induced early afterdepolarizations from 9/9 to /9. In isolated heart electrocardiogram recordings, WXKL inhibited ischemia-reperfusion induced ventricular premature beats and tachycardia. Conclusions WXKL attenuated [Ca2+]i overload induced by hypoxia-reoxygenation in ventricular myocytes through inhibiting INaL and ICaL and prevents arrhythmias. This could, at least partly, contribute to the antiarrhythmic effects of WXKL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Wenxin Keli diminishes Ca2+ overload induced by hypoxia/reoxygenation in cardiomyocytes through inhibiting INaL and ICaL.
- Author
-
Luo, Antao, Liu, Zhipei, Cao, Zhenzhen, Hao, Jie, Wu, Lin, Fu, Chen, Zeng, Mengliu, Jiang, Wanzhen, Zhang, Peihua, Zhao, Buchang, Zhao, Tao, Zhao, Jing, and Ma, Jihua
- Subjects
ARRHYTHMIA prevention ,HYPOXEMIA ,CALCIUM ,ELECTROCARDIOGRAPHY ,FLUOROSCOPY ,HEART cells ,HERBAL medicine ,CHINESE medicine ,METABOLIC disorders ,MYOCARDIUM ,SODIUM - Abstract
Background An increase in the late sodium current (I
NaL ) causes intracellular Na+ overload and subsequently intracellular Ca2+ ([Ca2+ ]i ) overload via the stimulated reverse Na+ -Ca2+ exchange (NCX). Wenxin Keli (WXKL) is an effective antiarrhythmic Chinese herb extract, but the underlying mechanisms are unclear. Methods and results The INaL , NCX current (INCX ), L-type Ca2+ current (ICaL ), and action potentials were recorded using the whole-cell patch-clamp technique in rabbit ventricular myocytes. Myocyte [Ca2+ ]i transients were measured using a dual excitation fluorescence photomultiplier system. WXKL decreased the enhanced INaL , reverse INCX , diastolic [Ca2+ ]i , and the amplitude of Ca2+ transients induced by sea anemone toxin II (ATX II, a specific INaL channel opener) in a concentration-dependent manner. Hypoxia increased INaL , INCX , and diastolic [Ca2+ ]i , and decreased amplitude of [Ca2+ ]i transients. Hypoxia-reoxygenation aggravated these changes and induced spontaneous [Ca2+ ]i transients and hypercontraction in 86% cells (6/7). The application of WXKL during hypoxia or reoxygenation periods decreased the increased INaL , INCX , and diastolic [Ca2+ ]i , and prevented those events in 82% cells (9/11) under hypoxia-reoxygenation conditions. WXKL also inhibited the ICaL in a dose-dependent manner. Furthermore, WXKL shortened the action potential duration and completely abolished ATX II-induced early afterdepolarizations from 9/9 to /9. In isolated heart electrocardiogram recordings, WXKL inhibited ischemia-reperfusion induced ventricular premature beats and tachycardia. Conclusions WXKL attenuated [Ca2+ ]i overload induced by hypoxia-reoxygenation in ventricular myocytes through inhibiting INaL and ICaL and prevents arrhythmias. This could, at least partly, contribute to the antiarrhythmic effects of WXKL. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. Wenxin Keli for Ventricular premature complexes with Heart failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- Author
-
Tian, Guihua, Li, Min, Qiu, Ruijin, Zhang, Xiaoyu, Li, Chengyu, Chen, Shiqi, Zhang, Qin, and Shang, Hongcai
- Abstract
Objective: To evaluate the efficacy and safety of Wenxin Keli (WXKL) alone or combined with Western medicine in treating ventricular premature complexes (VPCs) with heart failure (HF).Methods: We searched five databases to identify relevant randomized controlled trials (RCTs) published before May 2016. Two review authors independently searched and screened the literature, extracted the data as well as assessed the methodological quality of the included studies by using criteria from the Cochrane Handbook, and analyzed via using Review Manager 5.3 software.Results: Eight studies of WXKL were included. The results of the Meta-analysis showed that WXKL was more significant on the frequency of VPCs (MD=-427.08, 95% CI: -526.73∼-327.43, P<0.01), left ventricular ejection fraction (LVEF) (MD=-4.12, 95% CI: 2.97∼5.27, P<0.01), the total effect of VPCs (RR=0.48, 95% CI: 0.34∼0.69, P<0.01) and 6-min walking test (MD=28.05, 95% CI: 19.56∼36.54, P<0.01). The treatment group presented a significant reduction at left ventricular end-diastolic diameter (LVED) (MD=-3.94, 95% CI: -6.57∼-1.31, P<0.01) when treatment time was 12 weeks, however, there was no statistical difference at 8 weeks. In addition, the included trials generally showed low methodological quality.Conclusions: Wenxin Keli may be effective and safe for treating VPCs and HF. However, further RCTs of larger scale, multi-center/country, longer follow-up periods, and higher quality are still required to verify the efficacy of Wenxin Keli in ventricular premature beat with heart failure. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. Efficacy and safety of Chinese herbal medicine Wenxin Keli for ventricular premature be ats: A systematic review.
- Author
-
He, Mei, Lv, Zhan, Yang, Zheng-Wei, Huang, Jiu-Ling, and Liu, Fu
- Abstract
Background: To evaluate the efficacy and safety of the Chinese herbal extract Wenxin Keli, alone or in combination with Western medicine, for ventricular premature beats.Methods: This systematic review was registered at PROSPERO (registration number CRD42013003200). A systematic literature search of 8 core electronic databases and 3 clinical trial registries in Chinese and English, yielded 10 trials whose randomness verified by contacting the authors. The included trials were assessed by the Cochrane risk of bias tool.Results: Wenxin Keli might be more efficacious than placebo (Change of VPBs numbers, RR, 1.61, 95%CI, 1.48-1.76, P<0.00001, I2=0%;VPBs- related symptom, RR, 2.10, 95%CI, 1.91-2.30, P<0.00001, I2=0%), and the dual therapy of Wenxin Keli plus amiodarone might also be more effective than the monotherapy of amiodarone (Change of VPBs numbers, RR, 1.23, 95%CI, 1.10-1.39, P=0.0005, I2=0%; VPBs- related symptom, RR, 1.51., 95%CI, 1.30-1.76, P<0.00001, I2=0%), whereas Wenxin Keli might be comparable to metoprolol, propafenone or mexiletine (Change of VPBs numbers: metoprolol, RR, 1.01, 95%CI, 0.91-1.11, P=0.88, I2=0%; propafenone, RR, 1.05, 95%CI, 0.93-1.19, P=0.44, I2=0%; mexiletine, RR, 1.06, 95%CI, 0.96-1.17, P=0.28. VPBs- related symptom: metoprolol, RR, 0.95, 95%CI, 0.87-1.04, P=0.27, I2=0%, propafenone. RR, 1.10, 95%CI, 0.93-1.30, P=0.29, I2=29%, mexiletine,RR, 0.94, 95%CI, 0.78-1.12, P=0.47). Participants with ventricular premature beats' numbers<360 beats/h or with coronary heart disease benefited the most of the Wenxin Keli therapy (Change of VPBs numbers:RR, 1.10, 95%CI, 1.02-1.20, P=0.02, I2=44%; RR, 1.71, 95%CI, 1.18-2.49, P=0.005, I2=54%, respectively). The safety analysis revealed that Wenxin Keli did not statistically significant differed from the Western medicine in respect of the incidence of total adverse drug reactions (RR, 0.59, 95%CI, 0.35-1.01, P=0.05, I2=0%), but Wenxin Keli might be associated with a reduced risk of proarrhythmic reactions (P=0.007). The quality of the methodology of included trials was generally low. Several limitations existed that affected the validity of the findings, including the small sample size, insufficient randomization methods, poorly defined eligibility criteria, short duration of follow-up, absence of hard endpoints, and high risk of publication bias(P=0.013).Conclusions: Wenxin Keli might be a promising alternative and complementary medicine for ventricular premature beats. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. Antiarrhythmic effects and potential mechanism of WenXin KeLi in cardiac Purkinje cells.
- Author
-
Hou, Jian-Wen, Li, Wei, Guo, Kai, Chen, Xiao-Meng, Chen, Yi-He, Li, Chang-Yi, Zhao, Bu-Chang, Zhao, Jing, Wang, Hong, Wang, Yue-Peng, and Li, Yi-Gang
- Abstract
Background: Previous studies have demonstrated that WenXin KeLi (WXKL), a traditional Chinese medicine, can exert antiarrhythmic properties through complex multichannel inhibition, but its pharmacologic effect remains to be elucidated, especially in the cardiac conductive system.Objective: To explore the antiarrhythmic property of WXKL in cardiac Purkinje cells (PCs).Methods: PCs were isolated from rabbit hearts and action potentials (APs) and ion currents were recorded by whole-cell patch clamp technique. Anemonia toxin II (ATX-II) and isoproterenol (ISO) were used to induce early or delayed afterdepolarizations (EADs, DADs) or triggered activities (TAs).Results: WXKL (1 g/L and 5 g/L) significantly abbreviated the action potential duration (APD) of PCs in a dose- and rate-dependent manner. Treatment of PCs with ATX-II (2 nM) prolonged APD and induced EADs, which were significantly suppressed by WXKL. WXKL (1, 5 g/L) also inhibited ISO-induced EADs, DADs, and TAs. To reveal the ionic mechanisms, we studied the effects of WXKL on late sodium current (I(NaL)), peak sodium current (I(NaP)), and L-type calcium currents (ICaL) in PCs. WXKL-attenuated ATX-II (5 nM) induced I(NaL) augmentation and blocked I(NaL) with an IC50 of 4.3 ± 0.5 g/L, which is 3- to 4-fold more selective than that of I(NaP) (13.3 ± 0.9 g/L) and ICaL (17.6 ± 1.4 g/L). Moreover, WXKL exerted significantly less use-dependent block of I(NaP) than that of flecainide, indicating its lower proarrhythmic effect.Conclusions: WXKL exhibits antiarrhythmic properties in cardiac PCs via selective inhibition of I(NaL). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
17. Identification of linoleic acid as an antithrombotic component of Wenxin Keli via selective inhibition of p-selectin-mediated platelet activation.
- Author
-
Tao, Qianqian, Xiao, Guangxu, Wang, Taiyi, Zhang, Lei, Yu, Mingxing, Peng, Li, Han, Linhong, Du, Xiaoli, Han, Wenrun, He, Shuang, Lyu, Ming, and Zhu, Yan
- Subjects
- *
BLOOD platelet activation , *LINOLEIC acid , *PROTEIN kinase B , *MITOGEN-activated protein kinases , *ORAL drug administration - Abstract
Atrial fibrillation significantly increases the risk of thromboembolism and stroke. Wenxin Keli (WXKL) is a widely used Chinese patent medicine against arrhythmia but if it has antithrombotic activity is unknown. Since platelet activation is a critical factor in thrombosis and the key target for many antithrombotic drugs, this study aims to demonstrate the antithrombotic efficacy of WXKL. In vitro platelet activation experiments showed that WXKL significantly inhibited platelet adhesion and aggregation. The potential active monomers in WXKL were screened by in silico prediction and in vitro platelet aggregation/adhesion assays. From WXKL chemical fractions and more than 40 monomers, linoleic acid (LA) was identified as the strongest antiplatelet compound. Oral administration of WXKL (1.2 g/kg/day) and LA (50 mg/kg/day) for 7 days significantly improved FeCl3-induced carotid thrombus formation in ICR mice without prolonging bleeding time. Flow cytometry showed that both WXKL and LA inhibited the release of p-selectin after platelet activation. ELISA showed that WXKL and LA also inhibited the expression of 6-Keto-PGF1α in plasma of mice with thrombus, but had no obvious effect on the expression of TXB2. WXKL inhibited platelet activation by broadly inhibiting the phosphorylation of protein kinase B (Akt), mitogen-activated protein kinases (MAPKs) and phospholipase C (PLC) β3. In contrast, LA only inhibited the phosphorylation of PLCβ3. In conclusion, WXKL and its active component LA showed good antiplatelet and antithrombotic efficacy in vivo and in vitro. Mechanistically, the multicomponent Chinese medicine WXKL acts on multiple targets in the platelet activation pathway whereas its active monomer linoleic acid acts specifically on phospholipase C β3. [Display omitted] • Anti-arrhythmic compound Chinese medicine Wenxin Keli has significant antithrombotic effect in vitro and in vivo, providing an experimental basis for its use in treatment of myocardial infarction. • Antithrombotic activity screen of WXKL components identified linoleic acid as a main active ingredient. • WXKL and its active ingredient linoleic acid exert antithrombotic effect via selectively inhibiting P-selectin-mediated platelet activation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Protective effects of Wenxin Keli against cardiac arrhythmias (Review)
- Author
-
Shaohua Guo, Tong Liu, Shristi Dahal, Gary Tse, and Mengqi Gong
- Subjects
General Immunology and Microbiology ,Oncogene ,business.industry ,Cell ,Cancer ,Cell cycle ,medicine.disease ,Molecular medicine ,General Biochemistry, Genetics and Molecular Biology ,medicine.anatomical_structure ,Apoptosis ,medicine ,Cancer research ,Wenxin keli ,business - Published
- 2020
19. Wenxin Keli diminishes Ca2+ overload induced by hypoxia/reoxygenation in cardiomyocytes through inhibiting INaL and ICaL
- Author
-
Jihua Ma, Zhipei Liu, Mengliu Zeng, Zhenzhen Cao, Jie Hao, Wanzhen Jiang, Chen Fu, Lin Wu, Jing Zhao, Peihua Zhang, Antao Luo, Tao Zhao, and Buchang Zhao
- Subjects
0301 basic medicine ,Tachycardia ,business.industry ,Diastole ,General Medicine ,030204 cardiovascular system & hematology ,Pharmacology ,Hypoxia (medical) ,Afterdepolarization ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine ,Myocyte ,Wenxin keli ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Intracellular ,Ca2 overload - Abstract
Background An increase in the late sodium current (INaL ) causes intracellular Na+ overload and subsequently intracellular Ca2+ ([Ca2+ ]i ) overload via the stimulated reverse Na+ -Ca2+ exchange (NCX). Wenxin Keli (WXKL) is an effective antiarrhythmic Chinese herb extract, but the underlying mechanisms are unclear. Methods and results The INaL , NCX current (INCX ), L-type Ca2+ current (ICaL ), and action potentials were recorded using the whole-cell patch-clamp technique in rabbit ventricular myocytes. Myocyte [Ca2+ ]i transients were measured using a dual excitation fluorescence photomultiplier system. WXKL decreased the enhanced INaL , reverse INCX , diastolic [Ca2+ ]i , and the amplitude of Ca2+ transients induced by sea anemone toxin II (ATX II, a specific INaL channel opener) in a concentration-dependent manner. Hypoxia increased INaL , INCX , and diastolic [Ca2+ ]i , and decreased amplitude of [Ca2+ ]i transients. Hypoxia-reoxygenation aggravated these changes and induced spontaneous [Ca2+ ]i transients and hypercontraction in 86% cells (6/7). The application of WXKL during hypoxia or reoxygenation periods decreased the increased INaL , INCX , and diastolic [Ca2+ ]i , and prevented those events in 82% cells (9/11) under hypoxia-reoxygenation conditions. WXKL also inhibited the ICaL in a dose-dependent manner. Furthermore, WXKL shortened the action potential duration and completely abolished ATX II-induced early afterdepolarizations from 9/9 to /9. In isolated heart electrocardiogram recordings, WXKL inhibited ischemia-reperfusion induced ventricular premature beats and tachycardia. Conclusions WXKL attenuated [Ca2+ ]i overload induced by hypoxia-reoxygenation in ventricular myocytes through inhibiting INaL and ICaL and prevents arrhythmias. This could, at least partly, contribute to the antiarrhythmic effects of WXKL.
- Published
- 2017
20. Applying cooperative module pair analysis to uncover compatibility mechanism of Fangjis: An example of Wenxin Keli decoction
- Author
-
Pengqian Wang, Yanwei Xing, Tianmai He, Xiaoyu Zhang, Rui Zheng, Yang Sun, Hongcai Shang, and Ruijin Qiu
- Subjects
Male ,Decoction ,Computational biology ,Rats, Sprague-Dawley ,Fight-or-flight response ,03 medical and health sciences ,0302 clinical medicine ,Mitotic cell cycle ,Atrial Fibrillation ,Drug Discovery ,Animals ,Cluster Analysis ,Wenxin keli ,Radix ,Codonopsis ,030304 developmental biology ,Pharmacology ,0303 health sciences ,biology ,Mechanism (biology) ,Computational Biology ,Arrhythmias, Cardiac ,biology.organism_classification ,Rats ,Ion channel activity ,030220 oncology & carcinogenesis ,Anti-Arrhythmia Agents ,Drugs, Chinese Herbal - Abstract
Ethnopharmacological relevance Fangji is an ancient combinatorial formula. The compatibility mechanisms that how component herbs of Fangji work cooperatively to achieve the executive framework remain unexplored. Aim of the study Toexplore compatibility mechanism and systematical effects of Fangjis by taking Wenxin Keli decoction (WXKL), a classical Fangji constituted by Codonopsis Radix, PolygonatiRhizoma, Notoginseng Radix Et Rhizoma, Ambrum, and Nardostachyos Radix Et Rhizoma., as example. Main methods Here, we employed bioinformatics approach, including cluster analysis, cooperative module pair analysis, primary module identification, and proximity examination among target profile of herbs, to investigate compatibility characterization and anti-arrhythmia mechanism of WXKL. Finally, core mechanisms of WXKL were validatedby in vivo experiments. Results As a result, we identified 695 putative target proteins and 27 clusters (W-modules) inWXKL target network (W-network), in which W-module 1, 2, 4, 8, 10 were primary modules. The cooperative module pairs were W-module 2 and 4, W-module 2 and 8, and W-module 2 and 1, all of which existed in Codonopsis Radix- or Notoginseng Radix Et Rhizoma.-condition. And Nardostachyos Radix Et Rhizoma only yielded cooperation between W-module 1 and 2. The proximity of herbs’ target profiles of Codonopsis Radix and Notoginseng Radix Et Rhizoma were similar, and Nardostachyos Radix Et Rhizoma and Ambrum were similar. For the compatibility framework, Codonopsis Radix general regulated 70.67% targets and majority W-modules (81.48%) as sovereign herb, contributing to primary therapeutic effect, mainly involving neurohormonal regulation, vasomotor, inflammation and oxidative stress. Other herbs assisted Codonopsis Radix to enhance major outcomes through common modules, and acted as complementary roles through unique process including mitotic cell cycle, biosynthetic and catabolic process, etc. Furthermore, WXKL regulated 66.67% hub proteins of arrhythmia-network, 68.18% and 47.37% proteins in primary arrhythmia-module 1 and 2, mainly involving ion channel activity, neurohormonal regulation, and stress response processes, to constitute regulatory network focusing on cardiovascular, renal, nervous system, to reverse the pathological process of arrhythmia. In vivo experiments demonstrated WXKL can attenuate adrenergic activation induced sympathetic atrial fibrillation by inhibiting calmodulin expression (CaM) and ryanodine receptor 2 (RYR2) phosphorylation to regulate neurohormonal action. Conclusion This strategy provided an overarching view of anti-arrhythmia mechanism of WXKL and its internal compatibility, and may facilitate the understanding of compatibility in Fangjis from the perspectives of modern biology.
- Published
- 2021
21. Wenxin Keli Suppresses Ventricular Triggered Arrhythmias via Selective Inhibition of Late Sodium Current.
- Author
-
XUE, XIAOLIN, GUO, DONGLIN, SUN, HONGMEI, WANG, DAN, LI, JIANA, LIU, TENGXIAN, YANG, LIN, SHU, JUAN, and YAN, GAN‐XIN
- Subjects
- *
ANIMAL experimentation , *CHI-squared test , *DIGOXIN , *ELECTROCARDIOGRAPHY , *ELECTROPHYSIOLOGY , *HEART conduction system , *RESEARCH methodology , *BOTANIC medicine , *RABBITS , *RESEARCH funding , *SODIUM , *T-test (Statistics) , *TISSUE culture , *VENTRICULAR tachycardia , *LONG QT syndrome , *DOFETILIDE , *DESCRIPTIVE statistics , *VENTRICULAR arrhythmia , *CHEMICAL inhibitors - Abstract
Background Wenxin Keli is a popular Chinese herb extract that approximately five million Asians are currently taking for the treatment of a variety of ventricular arrhythmias. However, its electrophysiological mechanisms remain poorly understood. Methods and results The concentration-dependent electrophysiological effects of Wenxin Keli were evaluated in the isolated rabbit left ventricular myocytes and wedge preparation. Wenxin Keli selectively inhibited late sodium current (INa) with an IC50 of 3.8 ± 0.4 mg/mL, which was significantly lower than the IC50 of 10.6 ± 0.9 mg/mL (n = 6, P < 0.05) for the fast INa. Wenxin Keli produced a small but statistically significant QT prolongation at 0.3 mg/mL, but shortened the QT and Tp-e interval at concentrations ≥1 mg/mL. Wenxin Keli increased QRS duration by 10.1% from 34.8 ± 1.0 ms to 38.3 ± 1.1 ms (n = 6, P < 0.01) at 3 mg/mL at a basic cycle length of 2,000 ms. However, its effect on the QRS duration exhibited weak use-dependency, that is, QRS remained less changed at increased pacing rates than other classic sodium channel blockers, such as flecainide, quinidine, and lidocaine. On the other hand, Wenxin Keli at 1-3 mg/mL markedly reduced dofetilide-induced QT and Tp-e prolongation by attenuation of its reverse use-dependence and abolished dofetilide-induced early afterdepolarization (EAD) in four of four left ventricular wedge preparations. It also suppressed digoxin-induced delayed afterdepolarization (DAD) and ventricular tachycardias without changing the positive staircase pattern in contractility at 1-3 mg/mL in a separate experimental series (four of four). Conclusions Wenxin Keli suppressed EADs, DADs, and triggered ventricular arrhythmias via selective inhibition of late INa. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. Efficacy and safety of Wenxin Keli combined with metoprolol tartrate in the treatment of premature ventricular contractions: A systematic review and meta-analysis.
- Author
-
Huang P, Luo Y, Chen J, Xu J, Shi Y, Chen G, and Ma P
- Abstract
Background: Wenxin Keli (WXKL) has good clinical value in the treatment of premature ventricular contractions, but there is insufficient evidence to support it. This study evaluates the efficacy and safety of WXKL combined with metoprolol tartrate in the treatment of ventricular premature beats (VPCs)., Methods: We searched seven databases to identify randomized controlled trials (RCTs) for this study. Two reviewers independently screened and extracted the data. The Cochrane Manual criteria were used for methodological quality assessment. Meta-analyses were performed using Review Manager 5.4.1 software. Risk ratios (RR) were used for effect sizes for dichotomous data, demonstrated in effect sizes and 95% confidence intervals (CIs)., Results: A total of 11 RCTs of WXKL combined with metoprolol tartrate in the treatment of premature ventricular contractions were included in this study. Meta-analysis showed that WXKL combined with metoprolol tartrate (treatment group) was more effective than metoprolol tartrate (control group) in improving premature ventricular contractions (RR = 1.32, 95% CI: [1.24, 1.40], P < 0.00001); significantly improved the rate of premature ventricular contractions (RR = 1.32, 95% CI: [1.23, 1.41], P < 0.00001); there was no difference in adverse drug reactions compared with the control group (RR = 0.61, 95% CI: [0.35, 0.1.05], P = 0.08), but the number of adverse reactions ( n = 18) was less than that of the control group ( n = 32), and the severity was lower than that of the control group. The included studies only mentioned randomization and did not describe the generation of random sequences in detail., Conclusion: This study found that Wenxin Keli combined with metoprolol tartrate in the treatment of premature ventricular contractions increased the efficacy of the drug, reduced the occurrence of adverse reactions, and reduced the severity of adverse reactions. Due to the quality limitations of the included studies, more high-quality RCTs are needed in the future to provide more evidence for longer-term analyses., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Huang, Luo, Chen, Xu, Shi, Chen and Ma.)
- Published
- 2022
- Full Text
- View/download PDF
23. Screening and Identification of Cardioprotective Compounds From Wenxin Keli by Activity Index Approach and in vivo Zebrafish Model
- Author
-
Mirko Baruscotti, Buchang Zhao, Hao Liu, Shi Yang, Yi Wang, Xuechun Chen, Xiaoping Zhao, and Ke Qian
- Subjects
0301 basic medicine ,animal structures ,Ginsenoside-Re ,Traditional Chinese medicine ,030204 cardiovascular system & hematology ,Pharmacology ,Activity index ,arrhythmia ,drug screen ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,Wenxin Keli ,medicine ,Bioassay ,Pharmacology (medical) ,Terfenadine ,Wenxin keli ,Zebrafish ,biology ,Chemistry ,lcsh:RM1-950 ,zebrafish ,biology.organism_classification ,lcsh:Therapeutics. Pharmacology ,030104 developmental biology ,cardioprotection ,medicine.drug - Abstract
Wenxin Keli (WXKL) is a widely used Chinese botanical drug for the treatment of arrhythmia, which is consisted of four herbs and amber. In the present study, we analyzed the chemical composition of WXKL using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) to tentatively identify 71 compounds. Through typical separate procession, the total extract of WXKL was divided into fractions for further bioassays. Cardiomyocytes and zebrafish larvae were applied for assessment. In vivo arrhythmia model in Cmlc2-GFP transgenic zebrafish was induced by terfenadine, which exhibited obvious reduction of heart rate and occurrence of atrioventricular block. Dynamic beating of heart was recorded by fluorescent microscope and sensitive camera to automatically recognize the rhythm of heartbeat in zebrafish larvae. By integrating the chemical information of WXKL and corresponding bioactivities of these fractions, activity index (AI) of each identified compound was calculated to screen potential active compounds. The results showed that dozens of compounds including ginsenoside Rg1, ginsenoside Re, notoginsenoside R1, lobetyolin, and lobetyolinin were contributed to cardioprotective effects of WXKL. The anti-arrhythmic activities of five compounds were further validated in larvae model and mature zebrafish by measuring electrocardiogram (ECG). Our findings provide a successful example for rapid discovery of bioactive compounds from traditional Chinese medicine (TCM) by activity index based approach coupled with in vivo zebrafish model.
- Published
- 2018
24. Applying cooperative module pair analysis to uncover compatibility mechanism of Fangjis: An example of Wenxin Keli decoction.
- Author
-
Wang, Pengqian, He, Tianmai, Zheng, Rui, Sun, Yang, Qiu, Ruijin, Zhang, Xiaoyu, Xing, Yanwei, and Shang, Hongcai
- Subjects
- *
MYOCARDIAL depressants , *PROTEINS , *HERBAL medicine , *IN vivo studies , *INFLAMMATION , *BIOINFORMATICS , *OXIDATIVE stress , *CELL cycle , *DRUG synergism , *PLANT extracts , *CLUSTER analysis (Statistics) , *CALCIUM , *CHINESE medicine , *PHOSPHORYLATION , *PHARMACODYNAMICS - Abstract
Fangji is an ancient combinatorial formula. The compatibility mechanisms that how component herbs of Fangji work cooperatively to achieve the executive framework remain unexplored. Toexplore compatibility mechanism and systematical effects of Fangjis by taking Wenxin Keli decoction (WXKL), a classical Fangji constituted by Codonopsis Radix, PolygonatiRhizoma, Notoginseng Radix Et Rhizoma, Ambrum, and Nardostachyos Radix Et Rhizoma., as example. Here, we employed bioinformatics approach, including cluster analysis, cooperative module pair analysis, primary module identification, and proximity examination among target profile of herbs, to investigate compatibility characterization and anti-arrhythmia mechanism of WXKL. Finally, core mechanisms of WXKL were validatedby in vivo experiments. As a result, we identified 695 putative target proteins and 27 clusters (W-modules) inWXKL target network (W-network), in which W-module 1, 2, 4, 8, 10 were primary modules. The cooperative module pairs were W-module 2 and 4, W-module 2 and 8, and W-module 2 and 1, all of which existed in Codonopsis Radix- or Notoginseng Radix Et Rhizoma.-condition. And Nardostachyos Radix Et Rhizoma only yielded cooperation between W-module 1 and 2. The proximity of herbs' target profiles of Codonopsis Radix and Notoginseng Radix Et Rhizoma were similar, and Nardostachyos Radix Et Rhizoma and Ambrum were similar. For the compatibility framework, Codonopsis Radix general regulated 70.67% targets and majority W-modules (81.48%) as sovereign herb, contributing to primary therapeutic effect, mainly involving neurohormonal regulation, vasomotor, inflammation and oxidative stress. Other herbs assisted Codonopsis Radix to enhance major outcomes through common modules, and acted as complementary roles through unique process including mitotic cell cycle, biosynthetic and catabolic process, etc. Furthermore, WXKL regulated 66.67% hub proteins of arrhythmia-network, 68.18% and 47.37% proteins in primary arrhythmia-module 1 and 2, mainly involving ion channel activity, neurohormonal regulation, and stress response processes, to constitute regulatory network focusing on cardiovascular, renal, nervous system, to reverse the pathological process of arrhythmia. In vivo experiments demonstrated WXKL can attenuate adrenergic activation induced sympathetic atrial fibrillation by inhibiting calmodulin expression (CaM) and ryanodine receptor 2 (RYR2) phosphorylation to regulate neurohormonal action. This strategy provided an overarching view of anti-arrhythmia mechanism of WXKL and its internal compatibility, and may facilitate the understanding of compatibility in Fangjis from the perspectives of modern biology. [Display omitted] • We introduce an approach for systematical exploration of interaction and integration among herbs' target sets of fangjis. • This strategy may facilitate the understanding of compatibility mechanism that how herbs of a fangji work cooperatively. • This may improve the network-based drug discovery for fangjis as a combinatorial therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis
- Author
-
Jonathan M. Cordeiro, Alexander Burashnikov, Charles Antzelevitch, Brian K. Panama, Dan Hu, and Hector Barajas-Martinez
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Action Potentials ,030204 cardiovascular system & hematology ,Sodium Channels ,Article ,03 medical and health sciences ,Dogs ,0302 clinical medicine ,Sodium channel blocker ,Heart Rate ,Internal medicine ,medicine ,Animals ,Humans ,Myocytes, Cardiac ,Wenxin keli ,Heart Atria ,cardiovascular diseases ,Cells, Cultured ,business.industry ,Sodium channel ,Atrial fibrillation ,Effective management ,Models, Theoretical ,medicine.disease ,HEK293 Cells ,030104 developmental biology ,cardiovascular system ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Heart atrium ,Drugs, Chinese Herbal ,Sodium Channel Blockers - Abstract
Atrial-selective inhibition of cardiac sodium channel current (INa) and INa-dependent parameters has been shown to contribute to the safe and effective management of atrial fibrillation. The present study was designed to examine the basis for the atrial-selective actions of Wenxin Keli.Whole cell INa was recorded at room temperature in canine atrial and ventricular myocytes. Trains of 40 pulses were elicited over a range of pulse durations and interpulse intervals to determine tonic and use-dependent block. A Markovian model for INa that incorporates interaction of Wenxin Keli with different states of the channel was developed to examine the basis for atrial selectivity of the drug.Our data indicate that Wenxin Keli does not bind significantly to either closed or open states of the sodium channel, but binds very rapidly to the inactivated state of the channel and dissociates rapidly from the closed state. Action potentials recorded from atrial and ventricular preparations in the presence of 5g/L Wenxin Keli were introduced into the computer model in current clamp mode to simulate the effects on maximum upstroke velocity (Vmax). The model predicted much greater inhibition of Vmax in atrial vs. ventricular cells at rapid stimulation rates.Our findings suggest that atrial selectivity of Wenxin Keli to block INa is due to more negative steady-state inactivation, less negative resting membrane potential, and shorter diastolic intervals in atrial vs. ventricular cells at rapid activation rates. These actions of Wenxin Keli account for its relatively safe and effective suppression of atrial fibrillation.
- Published
- 2016
26. The Role of Traditional Chinese Herbal Medicines and Bioactive Ingredients on Ion Channels: A Brief Review and Prospect
- Author
-
Sheng Wang, Chen Jia, Ma Shumei, Nan Liu, Ben Chen, Yan Wang, Li Liu, Yian Huang, and Renjie Yan
- Subjects
Pharmacology ,Ligusticum chuanxiong ,Angelica sinensis ,Plants, Medicinal ,biology ,Traditional medicine ,business.industry ,General Neuroscience ,Traditional Chinese medicine ,biology.organism_classification ,Cannabis sativa ,Salvia miltiorrhiza ,Ion Channels ,Medicine ,Animals ,Humans ,Wenxin keli ,Drug/agent ,Curcuma ,Medicine, Chinese Traditional ,business ,Drugs, Chinese Herbal - Abstract
Traditional Chinese Medicines (TCMs), particularly the Chinese herbal medicines, are valuable sources of medicines and have been used for centuries. The term “TCMs” both represents to the single drug agent like Salvia miltiorrhiza, Ligusticum chuanxiong and Angelica sinensis, and those herbal formulas like Jingshu Keli, Wenxin Keli and Danzhen powder. In recent years, the researches of TCMs developed rapidly to understand the scientific basis of these herbs. In this review, we collect the studies of TCM and their containing bioactive compounds, and attempt to provide an overview for their regulatory effects on different ion channels including Ca2+, K+, Na+, Cl- channels and TRP, P2X receptors. The following conditions are used to limit the range of our review. (i) Only the herbal materials are included in this review and the animal- and mineral-original TCMs are excluded. (ii) The major discussions in this review focus on single TCM agent and the herbal formulas are only discussed for a little. (iii) Those most famous herbal medicines like Capsicum annuum (pepper), Curcuma longa (ginger) and Cannabis sativa (marijuana) are excluded. (iv) Only those TCM herbs with more than 5 research papers confirming their effects on ion channels are discussed in this review. Our review discusses recently available scientific evidences for TCMs and related bioactive compounds that have been reported with the modulatory effects on different ion channels, and thus provides a new ethnopharmacological approach to understand the usage of TCMs.
- Published
- 2018
27. Wenxin Keli for atrial fibrillation
- Author
-
He, Zhuogen, Zheng, Minan, Xie, Pingchang, Wang, Yuanping, Yan, Xia, and Deng, Dingwei
- Subjects
systematic review ,Research Design ,Study Protocol Systematic Review ,Wenxin Keli ,Atrial Fibrillation ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Humans ,protocol ,Research Article ,Drugs, Chinese Herbal ,Randomized Controlled Trials as Topic ,Systematic Reviews as Topic - Abstract
Supplemental Digital Content is available in the text, Background: Atrial fibrillation (AF) is a most common cardiac arrhythmia in clinical practice. In China, Wenxin Keli (WXKL) therapy is a common treatment for AF, but its effects and safety remain uncertain. This protocol is to provide the methods used to assess the effectiveness and safety of WXKL for the treatment of patients with AF. Methods: We will search comprehensively the 4 English databases EMBASE, the Cochrane Central Register of Controlled Trials (Cochrane Library), PubMed, and Medline and 3 Chinese databases China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), and Chinese Science and Technology Periodical database (VIP) on computer on March 2018 for the randomized controlled trials (RCTs) regarding WXKL for AF. The therapeutic effects according to the sinus rhythm and p-wave dispersion (Pwd) will be accepted as the primary outcomes. We will use RevMan V.5.3 software as well to compute the data synthesis carefully when a meta-analysis is allowed. Results: This study will provide a high-quality synthesis of current evidence of WXKL for AF. Conclusion: The conclusion of our systematic review will provide evidence to judge whether WXKL is an effective intervention for patient with AF. PROSPERO registration number: PROSPERO CRD 42018082045.
- Published
- 2018
28. Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation
- Author
-
Guangping Li, Tong Liu, Gary Tse, Gang Xu, Calista Zhuo Yi Chan, Mengqi Gong, Enzhao Liu, Nixiao Zhang, Shristi Dahal, Konstantinos P. Letsas, Yajuan Yang, and Panagiotis Korantzopoulos
- Subjects
medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Article Subject ,030204 cardiovascular system & hematology ,Amiodarone ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Medicine ,In patient ,Sinus rhythm ,Wenxin keli ,Recent onset ,Adverse effect ,business.industry ,Atrial fibrillation ,medicine.disease ,lcsh:RC666-701 ,030220 oncology & carcinogenesis ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Research Article - Abstract
Background. Use of amiodarone (AMIO) in atrial fibrillation (AF) has significant side effects over prolonged periods. Wenxin Keli (WXKL), a Chinese herb extract, has been shown to be effective in atrial-selective inhibiting peak INa and hence beneficial in treating atrial arrhythmias, including atrial fibrillation. The aim of this randomized controlled trial was to evaluate potential effects of AMIO plus WXKL on conversion rate and time in patients with recent-onset AF. Methods. A total of 41 patients (71 ± 12 years, 44% male) with recent-onset (n=21) or amiodarone with same dosage plus oral WXKL 18 g thrice daily (n=20) for 24 hours. Results. Conversion rate at 24 hours was of no difference between the two groups (75.0% vs. 81.0%, P=0.72); however, conversion time was markedly shorter in the AMIO + WXKL group compared to the AMIO group (291 ± 235 minutes vs. 725 ± 475 minutes, P=0.003). There were no serious adverse events during the study. Conclusion. Administration of amiodarone plus WXKL for recent-onset AF conversion was safe and effective, with faster sinus rhythm restoration compared with amiodarone alone.
- Published
- 2018
- Full Text
- View/download PDF
29. The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions
- Author
-
Runlin Gao, Wei Hua, Jing Wang, Shu Zhang, Xuhua Chen, Bu-Chang Zhao, and Chi Cai
- Subjects
Adult ,Male ,Cardiac function curve ,medicine.medical_specialty ,Pediatrics ,Efficacy ,Population ,lcsh:Medicine ,Traditional Chinese medicine ,Placebo ,Premature Ventricular Contractions ,law.invention ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,Multicenter trial ,Wenxin Keli ,medicine ,Humans ,education ,Aged ,education.field_of_study ,business.industry ,Safety ,Clinical Trial ,lcsh:R ,General Medicine ,Middle Aged ,Ventricular Premature Complexes ,Clinical trial ,Treatment Outcome ,Cohort ,Quality of Life ,Cardiology ,Female ,Original Article ,business ,Drugs, Chinese Herbal - Abstract
Background: Premature ventricular contractions (PVCs) are common in the general population, and frequent PVCs may result in the poor quality of life or even the damage of cardiac function. We examined the efficacy and safety of a traditional Chinese medicine Wenxin Keli for the treatment of frequent PVCs among a relatively large Chinese cohort. Methods: We performed a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. A total of 1200 eligible participants were randomly assigned in a ratio of 1:1 to receive Wenxin Keli or the placebo for 4 weeks. The primary and secondary endpoint was the change of PVC numbers and PVC-related symptoms after a 4-week treatment compared with baseline, respectively. In addition, vital signs, laboratory values, and electrocardiographic parameters were assessed in a safety analysis. Results: At the initial evaluation, no significant differences in the baseline characteristics were observed between the Wenxin Keli group and the placebo group. A smaller number of PVCs was observed after the 4-week treatment than at baseline, in both the Wenxin Keli group (5686 ± 5940 vs. 15,138 ± 7597 beats/d, P < 0.001) and the placebo group (10,592 ± 8009 vs. 14,529 ± 5929 beats/d, P < 0.001); moreover, the Wenxin Keli group demonstrated a significantli greater reduction in the frequency of PVCs than the placebo group (P < 0.001). In a full analysis set, patients in the Wenxin Keli group exhibited significantly higher total effective responses in the reduction of PVCs compared to those in the placebo group (83.8% vs. 43.5%, P < 0.001). The per-protocol analysis yielded similar results (83.0% vs. 39.3%, P < 0.001). Treatment with Wenxin Keli also demonstrated superior performance compared to the placebo with respect to PVC-related symptoms. No severe adverse effects attributable to Wenxin Keli were reported. Conclusions: Wenxin Keli treatment effectively reduced the overall number of PVCs and alleviated PVC-related symptoms in patients without structural heart diseases and had no severe side effects.
- Published
- 2015
30. Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study
- Author
-
Wei Zheng, Qing He, Jianping Zhang, Zhaowei Meng, Qiang Jia, Mei Zhu, Jian Tan, Xue Li, Guizhi Zhang, and Shen Wang
- Subjects
medicine.medical_specialty ,Article Subject ,Antithyroid drugs ,Paroxysmal atrial fibrillation ,business.industry ,Sotalol ,lcsh:Other systems of medicine ,lcsh:RZ201-999 ,law.invention ,Surgery ,Complementary and alternative medicine ,Randomized controlled trial ,law ,Antiarrhythmia drugs ,Anesthesia ,medicine ,Sinus rhythm ,Wenxin keli ,Open label ,business ,Research Article ,medicine.drug - Abstract
We aimed to compare effectiveness of Wenxin Keli (WK) and sotalol in assisting sinus rhythm (SR) restoration from paroxysmal atrial fibrillation (PAF) caused by hyperthyroidism, as well as in maintaining SR. We randomly prescribed WK (18 g tid) or sotalol (80 mg bid) to 91 or 89 patients. Since it was not ethical not to give patients antiarrhythmia drugs, no control group was set. Antithyroid drugs were given to 90 patients (45 in WK group, 45 in sotalol group);131I was given to 90 patients (46 in WK group, 44 in sotalol group). Three months later, SR was obtained in 83/91 or 80/89 cases from WK or sotalol groups(P=0.762). By another analysis, SR was obtained in 86/90 or 77/90 cases from131I or ATD groups(P=0.022). Then, we randomly assigned the successfully SR-reverted patients into three groups: WK, sotalol, and control (no antiarrhythmia drug was given) groups. After twelve-month follow-up, PAF recurrence happened in 1/54, 2/54, and 9/55 cases, respectively. Log-Rank test showed significant higher PAF recurrent rate in control patients than either treatment(P=0.06). We demonstrated the same efficacies of WK and sotalol to assist SR reversion from hyperthyroidism-caused PAF. We also showed that either drug could maintain SR in such patients.
- Published
- 2015
31. Wenxin Keli for Ventricular premature complexes with Heart failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- Author
-
Shiqi Chen, Xiaoyu Zhang, Hongcai Shang, Qin Zhang, Ruijin Qiu, Chengyu Li, Guihua Tian, and Min Li
- Subjects
Complementary and Manual Therapy ,Adult ,medicine.medical_specialty ,Ventricular Premature Complexes ,Heart Ventricles ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Outcome Assessment, Health Care ,Medicine ,Humans ,Wenxin keli ,Methodological quality ,Aged ,Advanced and Specialized Nursing ,Aged, 80 and over ,Heart Failure ,business.industry ,Review manager ,Stroke Volume ,Middle Aged ,medicine.disease ,Complementary and alternative medicine ,030220 oncology & carcinogenesis ,Meta-analysis ,Heart failure ,Cardiology ,business ,Western medicine ,Drugs, Chinese Herbal ,Phytotherapy - Abstract
To evaluate the efficacy and safety of Wenxin Keli (WXKL) alone or combined with Western medicine in treating ventricular premature complexes (VPCs) with heart failure (HF).We searched five databases to identify relevant randomized controlled trials (RCTs) published before May 2016. Two review authors independently searched and screened the literature, extracted the data as well as assessed the methodological quality of the included studies by using criteria from the Cochrane Handbook, and analyzed via using Review Manager 5.3 software.Eight studies of WXKL were included. The results of the Meta-analysis showed that WXKL was more significant on the frequency of VPCs (MD=-427.08, 95% CI: -526.73∼-327.43, P0.01), left ventricular ejection fraction (LVEF) (MD=-4.12, 95% CI: 2.97∼5.27, P0.01), the total effect of VPCs (RR=0.48, 95% CI: 0.34∼0.69, P0.01) and 6-min walking test (MD=28.05, 95% CI: 19.56∼36.54, P0.01). The treatment group presented a significant reduction at left ventricular end-diastolic diameter (LVED) (MD=-3.94, 95% CI: -6.57∼-1.31, P0.01) when treatment time was 12 weeks, however, there was no statistical difference at 8 weeks. In addition, the included trials generally showed low methodological quality.Wenxin Keli may be effective and safe for treating VPCs and HF. However, further RCTs of larger scale, multi-center/country, longer follow-up periods, and higher quality are still required to verify the efficacy of Wenxin Keli in ventricular premature beat with heart failure.
- Published
- 2016
32. Systematic review and meta-analysis of randomized controlled trials on Wenxin keli
- Author
-
Ying Wang, Xiaoyi Wang, Yu Zhang, Wentao Zhu, Ying Lu, Wenwen Wang, and Xiao Yuan Feng
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Pharmaceutical Science ,Review ,Cochrane Library ,law.invention ,Angina Pectoris ,Angina ,03 medical and health sciences ,Randomized controlled trial ,systematic review ,law ,cardiovascular disease ,Internal medicine ,Drug Discovery ,medicine ,Humans ,Wenxin keli ,Clinical efficacy ,Randomized Controlled Trials as Topic ,Pharmacology ,Heart Failure ,business.industry ,Arrhythmias, Cardiac ,Knowledge infrastructure ,medicine.disease ,meta-analysis ,Myocarditis ,030104 developmental biology ,Search terms ,Cardiovascular Diseases ,Virus Diseases ,Meta-analysis ,Female ,Menopause ,business ,Drugs, Chinese Herbal - Abstract
Objective The aim of the study was to evaluate the effectiveness, safety, and cost associated with Wenxin keli in the treatment of cardiovascular diseases based on meta-analysis. Methods The terms "Wenxin keli" and "Wenxin" were used as the search terms in the PubMed, ProQuest, Springer, the Cochrane Library, CNKI (China National Knowledge Infrastructure), VIP (Chinese Scientific Journals Database), and Wan fang electronic databases (from January 2000 to October 2015). Relevant print journals and conference papers were also searched. Studies on randomized controlled trials (RCTs) of Wenxin keli used in the treatment of cardiovascular diseases were screened, and its indications were classified. Meta-analysis of these studies was conducted using the RevMan 5.2 software. Results A total of 49 RCTs (n=4,610) were included, 29 of which focused on arrhythmia, seven on angina, seven on heart failure, two on viral myocarditis, and four on menopausal syndrome. Analysis of the therapeutic indications of Wenxin keli showed that it was comparatively more curative and effective than other available treatments for cardiovascular diseases. Conclusion Wenxin keli showed better clinical efficacy in the treatment of arrhythmia, angina, and heart failure; however, more high-quality evidence is needed to support its use in the clinical setting.
- Published
- 2016
33. Antiarrhythmic effects and potential mechanism of WenXin KeLi in cardiac Purkinje cells
- Author
-
Chang-Yi Li, Xiao-Meng Chen, Jing Zhao, Yi-Gang Li, Yi-He Chen, Bu-Chang Zhao, Hong Wang, Wei Li, Yue-Peng Wang, Kai Guo, and Jian-Wen Hou
- Subjects
0301 basic medicine ,Patch-Clamp Techniques ,chemistry.chemical_element ,Action Potentials ,030204 cardiovascular system & hematology ,Pharmacology ,Calcium ,Sodium current ,03 medical and health sciences ,Purkinje Cells ,0302 clinical medicine ,Heart Conduction System ,Physiology (medical) ,medicine ,Animals ,Wenxin keli ,Myocytes, Cardiac ,Patch clamp ,Potential mechanism ,Flecainide ,business.industry ,Arrhythmias, Cardiac ,Nap ,Electrophysiology ,030104 developmental biology ,chemistry ,Rabbits ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Drugs, Chinese Herbal - Abstract
Background Previous studies have demonstrated that WenXin KeLi (WXKL), a traditional Chinese medicine, can exert antiarrhythmic properties through complex multichannel inhibition, but its pharmacologic effect remains to be elucidated, especially in the cardiac conductive system. Objective To explore the antiarrhythmic property of WXKL in cardiac Purkinje cells (PCs). Methods PCs were isolated from rabbit hearts and action potentials (APs) and ion currents were recorded by whole-cell patch clamp technique. Anemonia toxin II (ATX-II) and isoproterenol (ISO) were used to induce early or delayed afterdepolarizations (EADs, DADs) or triggered activities (TAs). Results WXKL (1 g/L and 5 g/L) significantly abbreviated the action potential duration (APD) of PCs in a dose- and rate-dependent manner. Treatment of PCs with ATX-II (2 nM) prolonged APD and induced EADs, which were significantly suppressed by WXKL. WXKL (1, 5 g/L) also inhibited ISO-induced EADs, DADs, and TAs. To reveal the ionic mechanisms, we studied the effects of WXKL on late sodium current (I NaL ), peak sodium current (I NaP ), and L-type calcium currents (I CaL ) in PCs. WXKL-attenuated ATX-II (5 nM) induced I NaL augmentation and blocked I NaL with an IC 50 of 4.3 ± 0.5 g/L, which is 3- to 4-fold more selective than that of I NaP (13.3 ± 0.9 g/L) and I CaL (17.6 ± 1.4 g/L). Moreover, WXKL exerted significantly less use-dependent block of I NaP than that of flecainide, indicating its lower proarrhythmic effect. Conclusions WXKL exhibits antiarrhythmic properties in cardiac PCs via selective inhibition of I NaL .
- Published
- 2015
34. Correction: An integrated anti-arrhythmic target network of compound Chinese medicine Wenxin Keli revealed by combined machine learning and molecular pathway analysis
- Author
-
Qunqun Du, Yan Zhu, Zheng Li, Peng Zhang, Ming Lu, Yu-Ling Ma, Taiyi Wang, Xi Yao, Weiwei Xie, and Xiaonan Chen
- Subjects
0301 basic medicine ,business.industry ,Traditional Chinese medicine ,Molecular pathway ,Machine learning ,computer.software_genre ,03 medical and health sciences ,030104 developmental biology ,Anti arrhythmic ,Medicine ,Wenxin keli ,Artificial intelligence ,business ,Molecular Biology ,computer ,Biotechnology - Abstract
Correction for ‘An integrated anti-arrhythmic target network of a Chinese medicine compound, Wenxin Keli, revealed by combined machine learning and molecular pathway analysis’ by Taiyi Wang et al., Mol. BioSyst., 2017, 13, 1018–1030.
- Published
- 2017
35. The Effects of Wenxin Keli on Left Ventricular Ejection Fraction and Brain Natriuretic Peptide in Patients with Heart Failure: A Meta-Analysis of Randomized Controlled Trials
- Author
-
Yanwei Xing, Chenggang Wang, Jun Li, Yonghong Gao, Jie Wang, Xiaoqiu Liu, Xingyong Zhang, Chun-mei Wang, Ying Zhang, Xingjiang Xiong, Yu Chen, and Yanhui Xing
- Subjects
medicine.medical_specialty ,Ejection fraction ,Article Subject ,business.industry ,MEDLINE ,lcsh:Other systems of medicine ,medicine.disease ,Brain natriuretic peptide ,lcsh:RZ201-999 ,law.invention ,Complementary and alternative medicine ,Randomized controlled trial ,law ,Internal medicine ,Heart failure ,Meta-analysis ,medicine ,Cardiology ,Wenxin keli ,cardiovascular diseases ,Adverse effect ,business ,Research Article - Abstract
Objective. To evaluate the beneficial and adverse effects of Wenxin Keli (WXKL), either alone or in combination with Western medicine, on the left ventricular ejection fraction (LVEF) and plasma brain natriuretic peptide (BNP) in the treatment of heart failure (HF).Methods. Seven major electronic databases were searched to retrieve potential randomized controlled trials (RCTs) designed to evaluate the clinical effectiveness of WXKL, either alone or in combination with Western medicine, for HF, with the LVEF or BNP after eight weeks of treatment as main outcome measures. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook for Systematic Review of Interventions, Version 5.1.0, and analyzed using RevMan 5.1.0 software.Results. Eleven RCTs of WXKL were included. The methodological quality of the trials was generally evaluated as low. The risk of bias was high. The results of the meta-analysis showed that WXKL, either alone or in combination with Western medicine, was more effective in LVEF and BNP, compared with no medicine or Western medicine alone, in patients with HF or HF complicated by other diseases. Five of the trials reported adverse events, while the others did not mention them, indicating that the safety of WXKL remains uncertain.Conclusions. WXKL, either alone or in combination with Western medicine, appears to be more effective in improving the LVEF and BNP in patients with HF and HF complications.
- Published
- 2014
- Full Text
- View/download PDF
36. The Chinese herb extract Wenxin Keli: A promising agent for the management of atrial fibrillation.
- Author
-
Liu, Yang, Zhang, Zhiwei, Yang, Yajuan, Zhang, Nixiao, Li, Guangping, and Liu, Tong
- Subjects
- *
ATRIAL fibrillation , *DISEASE management , *HERBAL medicine , *PLANT extracts , *MYOCARDIAL depressants , *DISEASE prevalence , *CATHETER ablation , *MORTALITY - Published
- 2016
- Full Text
- View/download PDF
37. Effects of wenxin keli on the action potential and L-type calcium current in rats with transverse aortic constriction-induced heart failure
- Author
-
Yang Li, Wen Chen, Lixia Lou, Yonghong Gao, Yu Chen, Xiaoqiu Liu, Li-li Guo, Mingjing Zhao, Jie Wang, Aiming Wu, and Yanwei Xing
- Subjects
medicine.medical_specialty ,Pathology ,Article Subject ,business.industry ,Aortic constriction ,Gating ,lcsh:Other systems of medicine ,Calcium current ,medicine.disease ,lcsh:RZ201-999 ,Complementary and alternative medicine ,Heart failure ,Internal medicine ,Cardiology ,cardiovascular system ,Medicine ,Myocyte ,Wenxin keli ,Ventricular myocytes ,Patch clamp ,business ,Research Article - Abstract
Objective. We investigated the effects of WXKL on the action potential (AP) and the L-type calcium current (ICa-L) in normal and hypertrophied myocytes.Methods. Forty male rats were randomly divided into two groups: the control group and the transverse aortic constriction- (TAC-) induced heart failure group. Cardiac hypertrophy was induced by TAC surgery, whereas the control group underwent a sham operation. Eight weeks after surgery, single cardiac ventricular myocytes were isolated from the hearts of the rats. The APs andICa-Lwere recorded using the whole-cell patch clamp technique.Results. The action potential duration (APD) of the TAC group was prolonged compared with the control group and was markedly shortened by WXKL treatment in a dose-dependent manner. The current densities of theICa-Lin the TAC group treated with 5 g/L WXKL were significantly decreased compared with the TAC group. We also determined the effect of WXKL on the gating mechanism of theICa-Lin the TAC group. We found that WXKL decreased theICa-Lby accelerating the inactivation of the channels and delaying the recovery time from inactivation.Conclusions. The results suggest that WXKL affects the AP and blocked theICa-L, which ultimately resulted in the treatment of arrhythmias.
- Published
- 2013
38. The Effects of Wenxin Keli on P-Wave Dispersion and Maintenance of Sinus Rhythm in Patients with Paroxysmal Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
- Author
-
Tao Sun, Yanhui Xing, Shaoping Nie, Wen Chen, Yu Chen, Jie Wang, Yonghong Gao, Hai Gao, Zhenpeng Zhang, Xiaoqiu Liu, Yanwei Xing, Fei Teng, and Hongcai Shang
- Subjects
medicine.medical_specialty ,business.industry ,Paroxysmal atrial fibrillation ,MEDLINE ,Review Article ,lcsh:Other systems of medicine ,lcsh:RZ201-999 ,law.invention ,Complementary and alternative medicine ,Randomized controlled trial ,law ,Meta-analysis ,Internal medicine ,Medicine ,Wenxin keli ,In patient ,Sinus rhythm ,business ,Adverse effect - Abstract
Objective. To evaluate the beneficial and adverse effects of Wenxin Keli (WXKL), alone or combined with Western medicine, on P-wave dispersion (Pd) and maintenance of sinus rhythm for the treatment of paroxysmal atrial fibrillation (PAF).Methods. Seven major electronic databases were searched to retrieve randomized controlled trials (RCTs) designed to evaluate the clinical effectiveness of WXKL, alone or combined with Western medicine, for PAF, with Pd or maintenance rate of sinus rhythm as the main outcome measure. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook for Systematic Review of Interventions, version 5.1.0, and analysed using RevMan 5.1.0 software.Results. Fourteen RCTs of WXKL were included. The methodological quality of the trials was generally evaluated as low. The results of meta-analysis showed that WXKL, alone or combined with Western medicine, was more effective in Pd and the maintenance of sinus rhythm, compared with no medicine or Western medicine alone, in patients with PAF or PAF complicated by other diseases. Seven of the trials reported adverse events, indicating that the safety of WXKL is still uncertain.Conclusions. WXKL, alone or combined with Western medicine, appears to be more effective in improving Pd as well as maintenance of sinus rhythm in patients with PAF and its complications.
- Published
- 2013
39. Therapeutic Effects of Wenxin Keli in Cardiovascular Diseases: An Experimental and Mechanism Overview.
- Author
-
Tian G, Sun Y, Liu S, Li C, Chen S, Qiu R, Zhang X, Li Y, Li M, and Shang H
- Abstract
Cardiovascular diseases (CVDs) are the major public health problem and a leading cause of morbidity and mortality on a global basis. Wenxin Keli (WXKL), a formally classical Chinese patent medicine with obvious efficacy and favorable safety, plays a great role in the management of patients with CVDs. Accumulating evidence from various animal and cell studies has showed that WXKL could protect myocardium and anti-arrhythmia against CVDs. WXKL exhibited its cardioprotective roles by inhibiting inflammatory reaction, decreasing oxidative stress, regulating vasomotor disorders, lowering cell apoptosis, and protection against endothelial injure, myocardial ischemia, cardiac fibrosis, and cardiac hypertrophy. Besides, WXKL could effectively shorten the QRS and Q-T intervals, decrease the incidence of atrial/ventricular fibrillation and the number of ventricular tachycardia episodes, improve the severity of arrhythmias by regulating various ion channels with different potencies, mainly comprising peak sodium current (I
Na ), late sodium current (INaL ), transient outward potassium current (Ito ), L-type calcium current (ICaL ), and pacemaker current (If ).- Published
- 2018
- Full Text
- View/download PDF
40. Clinical Safety and Efficacy of Wenxin Keli-Amiodarone Combination on Heart Failure Complicated by Ventricular Arrhythmia: A Systematic Review and Meta-analysis.
- Author
-
Zheng R, Tian G, Zhang Q, Wu L, Xing Y, and Shang H
- Abstract
Objectives: To evaluate possible adverse effects and efficacy of Wenxin keli (WXKL)-amiodarone combination on heart failure complicated by ventricular arrhythmia. Methods: Nine electronic literature databases (the Cochrane Library, PubMed, EMBASE, IPA, AMED, CBM, CNKI, VIP, and WanFang) were searched up to February 2018. Two authors extracted data and assessed risk of bias of the included studies independently. Randomized controlled trials (RCTs) and quasi-RCTs about WXKL-amiodarone combination and amiodarone alone were eligible for comparison. Results: Thirteen trials involving 1,126 patients were included. Risk of bias was assessed as high in three studies and unclear in the remaining 10 studies. Six trials reported adverse events (AE). There was no obvious difference between WXKL-amiodarone combination group and amiodarone group in reported AEs (OR 0.64; 95%CI 0.39-1.07). The total effective rate of WXKL-amiodarone combination group was greater than that of amiodarone group (RR 1.22; 95%CI 1.16-1.29). The pooled results showed that the combination group was more effective in reducing heart rate (MD -2.25; 95%CI -2.61 to -1.88, P = 0.46, I
2 = 0%), the frequency of ventricular premature complexes (MD -2.03; 95%CI -2.41 to -1.65) and QT dispersion (MD 5.59; 95%CI 3.60-7.58). Conclusion: The WXKL-amiodarone combination is safe and shows more protective effects on heart failure combined with ventricular arrhythmia compared with amiodarone alone. Further research is warranted, ideally involving large, prospective, rigorous trials, in order to confirm these findings.- Published
- 2018
- Full Text
- View/download PDF
41. Wenxin Keli diminishes Ca 2+ overload induced by hypoxia/reoxygenation in cardiomyocytes through inhibiting I NaL and I CaL .
- Author
-
Luo A, Liu Z, Cao Z, Hao J, Wu L, Fu C, Zeng M, Jiang W, Zhang P, Zhao B, Zhao T, Zhao J, and Ma J
- Subjects
- Animals, Cell Hypoxia physiology, Female, Male, Rabbits, Anti-Arrhythmia Agents pharmacology, Calcium metabolism, Drugs, Chinese Herbal pharmacology, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Oxygen metabolism, Sodium metabolism
- Abstract
Background: An increase in the late sodium current (I
NaL ) causes intracellular Na+ overload and subsequently intracellular Ca2+ ([Ca2+ ]i ) overload via the stimulated reverse Na+ -Ca2+ exchange (NCX). Wenxin Keli (WXKL) is an effective antiarrhythmic Chinese herb extract, but the underlying mechanisms are unclear., Methods and Results: The INaL , NCX current (INCX ), L-type Ca2+ current (ICaL ), and action potentials were recorded using the whole-cell patch-clamp technique in rabbit ventricular myocytes. Myocyte [Ca2+ ]i transients were measured using a dual excitation fluorescence photomultiplier system. WXKL decreased the enhanced INaL , reverse INCX , diastolic [Ca2+ ]i , and the amplitude of Ca2+ transients induced by sea anemone toxin II (ATX II, a specific INaL channel opener) in a concentration-dependent manner. Hypoxia increased INaL , INCX , and diastolic [Ca2+ ]i , and decreased amplitude of [Ca2+ ]i transients. Hypoxia-reoxygenation aggravated these changes and induced spontaneous [Ca2+ ]i transients and hypercontraction in 86% cells (6/7). The application of WXKL during hypoxia or reoxygenation periods decreased the increased INaL , INCX , and diastolic [Ca2+ ]i , and prevented those events in 82% cells (9/11) under hypoxia-reoxygenation conditions. WXKL also inhibited the ICaL in a dose-dependent manner. Furthermore, WXKL shortened the action potential duration and completely abolished ATX II-induced early afterdepolarizations from 9/9 to /9. In isolated heart electrocardiogram recordings, WXKL inhibited ischemia-reperfusion induced ventricular premature beats and tachycardia., Conclusions: WXKL attenuated [Ca2+ ]i overload induced by hypoxia-reoxygenation in ventricular myocytes through inhibiting INaL and ICaL and prevents arrhythmias. This could, at least partly, contribute to the antiarrhythmic effects of WXKL., (© 2017 Wiley Periodicals, Inc.)- Published
- 2017
- Full Text
- View/download PDF
42. The Chinese herb extract Wenxin Keli: Atrial selectivity from the Far East
- Author
-
Uma Mahesh R. Avula and Jérôme Kalifa
- Subjects
medicine.medical_specialty ,Ventricular tissue ,Extramural ,business.industry ,Atrial tissue ,Physiology (medical) ,Internal medicine ,Anesthesia ,cardiovascular system ,medicine ,Cardiology ,Wenxin keli ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business ,Perfusion ,Maximum rate - Abstract
The authorshave implemented an isolated canine perfused right atrialpreparation—appended to a rim of right ventricular tissue—and recorded atrial and ventricular transmembrane actionpotentials and pseudo-electrograms before and after intra-coronary perfusion of various concentrations of WenxinKeli. Interestingly, Wenxin Keli produced effects more no-ticeable in atrial tissue than in ventricular tissue, as it causedaction potential duration (APD) shortening and postrepolar-ization refractoriness—which is a prolongation of effectiverefractory periods without APD prolongation—in an atrial-selective manner. In addition, Wenxin Keli produced agreater reduction in the maximum rate of rise of the actionpotential upstroke and a larger increase in the diastolicthreshold for excitation in atrial vs ventricular cells, sug-gestive of I
- Published
- 2012
43. Wenxin Keli for Ventricular premature complexes with Heart failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- Author
-
Li M, Qiu R, Tian G, Zhang X, Li C, Chen S, Zhang Q, and Shang H
- Subjects
- Adult, Aged, Aged, 80 and over, Drugs, Chinese Herbal pharmacology, Heart Failure complications, Heart Ventricles pathology, Heart Ventricles physiopathology, Humans, Middle Aged, Outcome Assessment, Health Care, Stroke Volume, Ventricular Premature Complexes etiology, Drugs, Chinese Herbal therapeutic use, Heart Failure drug therapy, Heart Ventricles drug effects, Phytotherapy, Ventricular Premature Complexes drug therapy
- Abstract
Objective: To evaluate the efficacy and safety of Wenxin Keli (WXKL) alone or combined with Western medicine in treating ventricular premature complexes (VPCs) with heart failure (HF)., Methods: We searched five databases to identify relevant randomized controlled trials (RCTs) published before May 2016. Two review authors independently searched and screened the literature, extracted the data as well as assessed the methodological quality of the included studies by using criteria from the Cochrane Handbook, and analyzed via using Review Manager 5.3 software., Results: Eight studies of WXKL were included. The results of the Meta-analysis showed that WXKL was more significant on the frequency of VPCs (MD=-427.08, 95% CI: -526.73∼-327.43, P<0.01), left ventricular ejection fraction (LVEF) (MD=-4.12, 95% CI: 2.97∼5.27, P<0.01), the total effect of VPCs (RR=0.48, 95% CI: 0.34∼0.69, P<0.01) and 6-min walking test (MD=28.05, 95% CI: 19.56∼36.54, P<0.01). The treatment group presented a significant reduction at left ventricular end-diastolic diameter (LVED) (MD=-3.94, 95% CI: -6.57∼-1.31, P<0.01) when treatment time was 12 weeks, however, there was no statistical difference at 8 weeks. In addition, the included trials generally showed low methodological quality., Conclusions: Wenxin Keli may be effective and safe for treating VPCs and HF. However, further RCTs of larger scale, multi-center/country, longer follow-up periods, and higher quality are still required to verify the efficacy of Wenxin Keli in ventricular premature beat with heart failure., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
44. Systematic review and meta-analysis of randomized controlled trials on Wenxin keli.
- Author
-
Wang X, Wang Y, Feng X, Lu Y, Zhang Y, Wang W, and Zhu W
- Subjects
- Angina Pectoris drug therapy, Arrhythmias, Cardiac drug therapy, Drugs, Chinese Herbal adverse effects, Female, Heart Failure drug therapy, Humans, Male, Menopause, Myocarditis drug therapy, Randomized Controlled Trials as Topic, Virus Diseases drug therapy, Cardiovascular Diseases drug therapy, Drugs, Chinese Herbal therapeutic use
- Abstract
Objective: The aim of the study was to evaluate the effectiveness, safety, and cost associated with Wenxin keli in the treatment of cardiovascular diseases based on meta-analysis., Methods: The terms "Wenxin keli" and "Wenxin" were used as the search terms in the PubMed, ProQuest, Springer, the Cochrane Library, CNKI (China National Knowledge Infrastructure), VIP (Chinese Scientific Journals Database), and Wan fang electronic databases (from January 2000 to October 2015). Relevant print journals and conference papers were also searched. Studies on randomized controlled trials (RCTs) of Wenxin keli used in the treatment of cardiovascular diseases were screened, and its indications were classified. Meta-analysis of these studies was conducted using the RevMan 5.2 software., Results: A total of 49 RCTs (n=4,610) were included, 29 of which focused on arrhythmia, seven on angina, seven on heart failure, two on viral myocarditis, and four on menopausal syndrome. Analysis of the therapeutic indications of Wenxin keli showed that it was comparatively more curative and effective than other available treatments for cardiovascular diseases., Conclusion: Wenxin keli showed better clinical efficacy in the treatment of arrhythmia, angina, and heart failure; however, more high-quality evidence is needed to support its use in the clinical setting., Competing Interests: The authors report no conflicts of interest in this work.
- Published
- 2016
- Full Text
- View/download PDF
45. Wenxin Keli suppresses atrial substrate remodelling after epicardial ganglionic plexi ablation.
- Author
-
Xiao J, Zhao Q, Kebbati AH, Deng H, Wang X, Dai Z, Yu S, and Huang C
- Abstract
Background: The chronic effects of ganglionic plexi (GP) ablation on atrial fibrillation (AF) inducibility have not been elucidated., Objective: To investigate the effect of Wenxin Keli (WK) on the inducibility of AF and atrial substrate remodelling after epicardial GP ablation., Methods: Twenty dogs were randomly divided into a sham-operated group, a GP ablation group and a WK-treated group. All animals underwent a left thoracotomy at the fourth intercostal space. AF inducibility was assessed by burst rapid pacing at the right atrium. Both the GP ablation group and the WK-treated group received four major GP ablations. In the WK-treated group, dogs were treated with oral WK once per day, and all animals were allowed to recover for eight weeks, after which AF inducibility and AF duration were measured again., Results: After eight weeks of WK treatment, AF inducibility was lower than in the GP ablation group, and was similar to that of the sham-operated group. Compared with the sham-operated group, the levels of atrial natriuretic peptide (ANP), tumour necrosis factor-alpha (TNF-α) and interleukin (IL)-6 in right atrial tissues were increased in GP ablation group (143.6±33.7 pg/mg versus 206.2±41.4 pg/mg, P=0.02; 75.3±12.1 pg/mg versus 141.3±64 pg/mg, P=0.03; and 175.1±42.5 pg/mg versus 351.7±101 pg/mg, P<0.01, respectively). There were no significant differences in levels of ANP, TNF-α and IL-6 in atrial tissues between the sham-operated group and WK treated group. Expression of connexin 43 in atrial tissues was increased after eight weeks of GP ablation, while WK administration inhibited connexin 43 remodelling., Conclusions: Epicardial GP ablation can induce atrial substrate remodelling, including Cx43 upregulation and increased levels of ANP, TNF-α and IL-6. These changes may be suppressed by long-term oral WK administration.
- Published
- 2013
46. GW26-e4625 Inhibitions of Wenxin Keli on ventricular arrhythmias with various underlying mechanisms
- Author
-
Shandong Yu, Yanpeng Chu, Lu Ren, Wei Yang, Lin Wu, Yong Huo, and Qiaomei Yang
- Subjects
business.industry ,cardiovascular system ,Medicine ,Wenxin keli ,cardiovascular diseases ,Traditional Chinese medicine ,Pharmacology ,business ,Cardiology and Cardiovascular Medicine ,Sodium current - Abstract
The antiarrhythmic effects of Wenxin Keli, the first state-sanctioned traditional Chinese medicine to treat cardiac arrhythmias, has been attributed to the inhibition of late sodium current. The purpose of this study was to determine the effects of Wenxin Keli on ventricular arrhythmias in rabbit
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.